VV
Vivoryon Therapeutics N.V.
VVY.AS · AMS
1.11 € -2.21% (-0.03 €)
1M -1.74%
Market Cap 32.7M €
P/E Ratio -
Div. Yield -
ROE 204.07%
Bulios Fair Price
0.89 €
19.5% downside
Current Price
1.11 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VVY.AS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 6.92x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 43.71%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 204.07%
ROA 117.76%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 7.68x
Int. coverage -203.93x
Debt/Equity 0.02x
Stability
49 /100
Moderate EPS volatility 23.12%
Profitable years 0
Beta 1.44x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VVY.AS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Frank T. Weber
Employees
13
Headquarters
Halle
Upcoming events
03 NOV
Earnings
Upcoming earnings report